logo-loader

US stocks close sharply lower as tech stock continue retreating

Last updated: 16:05 23 Sep 2020 EDT, First published: 08:11 23 Sep 2020 EDT

Johnson & Johnson - Wall Street points to higher open on Wednesday

4:05pm: US stocks tank again

US stocks closed sharply lower Wednesday, as tech stock retreated again amid fiscal stimulus uncertainty and COVID-19 anxiety. 

The Dow Jones Industrial Average fell 1.92%, or 525 points, to 26,763, after being close to 180 points higher earlier in the session. The DJIA is now facing its worst weekly slump since June. 

The S&P 500 tanked 2.37% to 3,236 and the tech-heavy Nasdaq dropped  3% to 10,632.

Amazon.com Inc (NASDAQ:AMZN), Apple Inc (NASDAQ:AAPL) and Tesla Inc (NASDAQ:TSLA) lead the steep decline in tech stocks. Tesla shares decreased by 10.3%.  

12:15 pm: Dow drops from up 200 to down more than 80

The major indices started up but turned sharply into the red by midday. The Dow Jones lost 109 points, 0.4%, to 27,178.5; the Nasdaq dropped 146 points, 1.4%, to 10,815; and the S&P 500 slipped 26 points, 0.8%, to 3,289.

Tech shares, as ever, are driving things: Amazon.com Inc (NASDAQ:AMZN) fell 2.3% to $3,058.9 and Alphabet Inc (NASDAQ:GOOG) declined 2.2% to $1,433.5.

Loretta Mester, president of the Cleveland Federal Reserve, said that accommodative monetary and fiscal policy was required to support the US economy, UK analyst David Madden noted Wednesday. Traders will be listening out for commentary from Jerome Powell, the Fed chief, and other central bankers were are due to speak today, he said.

10.15am - Proactive North America headlines:

Japan Gold Corp (CVE:JG) (OTCQB:JGLDF) says its alliance with Barrick Gold has acquired new project on Japanese island of Hokkaido

First Cobalt Corp (CVE:FCC) (OTCQX:FTSSF) says cobalt will remain a key component of electric vehicle batteries after Tesla's Battery Day announcement

NexTech AR (OTCQB:NEXCF) (CSE:NTAR) wins $900,000 in bookings for its popular video conferencing and virtual events platform InfernoAR

CleanSpark Inc (NASDAQ:CLSK) receives contract to provide intelligent switchgear upgrades and support for a US Embassy located on the African continent

Humanigen Inc (NASAQ:HGEN) inks partnership with Thermo Fisher to speed production of coronavirus drug lenzilumab

Biocept Inc (NASDAQ:BIOC), wins Japanese patent for its Primer-Switch technology to detect rare mutations and cancer biomarkers

Thoughtful Brands Inc (CSE:TBI) (OTCQB:PEMTF) raises $600K in private placement to settle debts and fund JV

CytoDyn Inc (OTCQB:CYDY) selected to make oral presentation at the “Special isirv-AVG Virtual Conference on Therapeutics for COVID-19”

Co-Diagnostics' detection of infectious disease has led it to join the coronavirus fight with flagship test

International Montoro Resources (CVE:IMT)(FRA:O4T1) acquires two high grade gold projects in potential district scale camp in Newfoundland

Wall Street has started on something of a mixed footing on Wednesday, with the tech-dominated Nasdaq proving to be the laggard among the main three indices.

Shortly after the opening bell, the Nasdaq Composite index was down 0.06% at 10,956, while the Dow Jones Industrial Average climbed 0.52% to 27,429 and the S&P 500 rose 0.12% to 3,319.

One of the weights on the Nasdaq is Tesla Inc (NASDAQ:TSLA), which saw its shares tumble  4.6% to US$404 in the early minutes of trading after its much anticipated ‘Battery Day’ failed to deliver the announcements investors had expected.

8.11am: Wall Street points to higher open on Wednesday

The main Wall Street indices are expected to add to Tuesday’s gains at the open.

Both European and US stocks are recovering following Monday’s losses amid worries of stricter restrictions over the winter, while some economic data due today could help or hinder sentiment.

The economic recovery was better than expected but short-lived, analysts point out, and the winter months ahead are forecast to be tough.

The Fed may also find itself under more pressure to use its powers and the newly agreed framework soon, with Congressional testimony by Fed chair Jerome Powell later today potentially unveiling more details of how exactly the central bank plans to deploy its resources in the months ahead.

“The only upside as far as markets are concerned is that more stimulus won't be far behind,” noted Craig Erlam, analyst at OANDA.

“This was certainly the message on Tuesday from Fed Chair Jerome Powell and Treasury Secretary Steve Mnuchin, although the fiscal side of the equation is proving problematic and may not come until after the election. A lot of damage can occur in the interim.”

Five things to watch for on Wednesday:

  • Federal Reserve chair Jerome Powell will deliver testimony to the Financial Services Committee of the US House of Representatives this afternoon, with the focus likely to be on the central bank’s outlook for the coming months as the US economy continues to struggle with the effects of the pandemic
  • There will also be some macroeconomic data in the form of flash PMI for the US manufacturing and services sectors for the month of September. The readings will provide some insight on the stage of the US economic recovery as the election nears, and may provide some insight ahead of jobs data next week
  • Aside from Powell’s congressional testimony, the Vice chair of the Fed Randal Quarles is also scheduled to speak as well as the president’s of the Chicago, Boston and Atlanta Fed branches
  • Share price reaction from Johnson & Johnson (NYSE:JNJ) following news that the drug maker’s coronavirus vaccine candidate has entered late-stage testing
  • Other firms eyed for share reactions include Nike Inc (NYSE:NKE) following an earnings beat late on Tuesday, as well as Tesla Inc (NASDAQ:TSLA) after investors were left unenthused by its ‘Battery Day’ event

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 6 minutes ago